NHS reverses decision and approves breast cancer drug Enhertu for around a thousand women a year
NICE rejected the drug on cost grounds in 2024. A higher cost-effectiveness threshold, introduced as part of a deal with the Trump administration in April, and a commercial discount on Enhertu's list price of more than £100,000 a year cleared the way for Thursday's approval.
2 min read